Change over period: —
NSE · NATHBIOGEN
NATH BIOGEN
-31.8% from the 52-week high · +3.6% above the low
Nath Bio-Genes (India) Ltd. engages in the production and marketing of seeds. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2014-01-28. The firm is engaged in the Seed Cultivation segment. The Company’s products categories include oilseeds and fiber, field crops, vegetables and plant nutrition. Its fiber and oils seeds include cotton and mustard. The firm's vegetable crop range includes chili, okra, tomato, bottle gourd, bitter gourd, cucumber, coriander, pumpkin, tinda and others. Its field corps include corn, jowar, hybrid paddy, research paddy and wheat. Its plant nutrition products include WINPro GOLii, WINall and Win Chin Win. Its forage products include NUTRIMAX and NUTRIMAX GOLD. The firm has seed processing facilities processing plants located in Maharashtra, Telangana and Andhra Pradesh. The firm also has processing arrangements in Gujarat, Karnataka, Tamil Nadu, Madhya Pradesh and Rajasthan on custom basis.
The short version. NATH BIOGEN reported revenue of ₹41 crore for Sep 2026, down 6.8% from a year earlier. Net profit was ₹0 crore (down 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 45.6% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
NATH BIOGEN trades 31.8% below its 52-week high and 3.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹41 cr.
5.3 pts lower than a year earlier.
Revenue compounded at 14.5% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 328 | 52 | 66 | 44 | 284 | 52 | 37 |
| Net profit | 0 | 32 | 0 | 2 | 3 | 37 | 1 | 3 |
| Net margin % | 1.0 | 9.8 | -0.0 | 2.4 | 6.3 | 13.1 | 2.8 | 7.2 |
| EPS (₹) | 0.22 | 16.98 | 0.0 | 0.84 | 1.45 | 19.62 | 0.78 | 1.39 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 445 | 365 | 333 | 301 |
| Net profit | 42 | 39 | 40 | 35 |
| Net margin % | 9.4 | 10.6 | 11.9 | 11.6 |
| EPS (₹) | 21.91 | 20.31 | 20.85 | 18.43 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.1% in Mar 2026; debt to equity is 0.20.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 6.1 | 6.0 | 6.5 | 6.1 |
| Return on capital % | 8.9 | 7.7 | 8.2 | 8.0 |
| EBITDA margin % | 14.6 | 14.9 | 16.2 | 16.3 |
| Net margin % | 9.2 | 10.4 | 11.9 | 11.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 14.5% | — |
| Profit CAGR | 5.9% | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Unchanged over 8 quarters.
Down 4.36 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 0.0 |
| FII | 0.19 | 0.21 | 0.42 | 0.32 | 0.31 | 0.23 | 0.27 | 0.19 | 0.0 |
| DII | 4.37 | 3.94 | 2.25 | 0.76 | 0.01 | 0.01 | 0.01 | 0.01 | -4.36 |
| Public | 49.84 | 50.25 | 51.74 | 53.32 | 54.08 | 54.17 | 54.13 | 54.21 | +4.37 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for NATH BIOGEN are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Agricultural Food & other Products stocks
Quick answers
Common questions about NATH BIOGEN
What is the NATH BIOGEN share price?
NATH BIOGEN (NATHBIOGEN) last closed at ₹133.02, down 0.46% on the day. Its 52-week range is ₹129.02 to ₹196.01.
What is the market cap of NATH BIOGEN?
NATH BIOGEN has a market capitalisation of about ₹255 crore. Its price-to-earnings ratio is 7.0.
How are NATH BIOGEN's latest results?
NATH BIOGEN reported revenue of ₹41 crore for Sep 2026, down 6.8% from a year earlier. Net profit was ₹0 crore (down 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 45.6% in Sep 2026, up 0.00 points over 8 quarters.
Who owns NATH BIOGEN?
As of Sep 2026, shareholding was: Promoter 45.6%, FII 0.19%, DII 0.01%, Public 54.21%.
How many mutual funds hold NATH BIOGEN?
0 mutual fund schemes held NATH BIOGEN in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 14 Aug 2025 · Final Dividend - Rs. 2
- 09 Aug 2024 · Final Dividend - Rs. 2
- 04 Jul 2023 · Final Dividend - Rs. 2
- 23 Jun 2022 · Dividend - Rs. 2
- 18 Aug 2021 · Final Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.